To ensure that “breakthrough therapies” provide a real advance over existing therapy, FDA is clarifying that to qualify for the designation established under FDASIA, a candidate generally should be compared to a current standard of care that is FDA-approved for the same indication.
The agency’s first official instructions on the breakthrough therapy designation created under the FDA Safety and Innovation Act come as part of a new draft guidance on expedited...